All of our reports are available via individual purchase or as part of a subscription to our Medtech Pro platform, which includes a full library of reports.
Abbott Laboratories
ACMI Corporation
American Medical Systems
AstraZeneca plc
Beckman Coulter (Hybritech)
B-K Medical Corporation
C.R. Bard
EDAP Technomed
Endocare
Focus Surgery
Gyrus Medical
Laborie Medical Technologies
Laserscope
Life-Tech
Medtronic
Mentor Corporation
Oakwood Laboratories
Oncura (Amersham Health, Galil Medical)
Praecis Pharmaceuticals
ProstaLund
TAP Pharmaceuticals
Theragenics
Urologix
Varian Medical Systems
EXECUTIVE SUMMARY
Diagnosis
Prostatitis
Benign Prostatic Hyperplasia
Prostate Cancer
Companies
Summary Exhibit 1: Prostate Diseases, Patient Forecasts, 2001-2008
Summary Exhibit 2: Prostate Diagnosis, Procedure & Market Forecast, 2001-2008
Summary Exhibit 3: Patients Treated for BPH by Modality, 2001-2008
Summary Exhibit 4: Prostate Cancer Treatments, Patient Forecast, 2001-2008
Summary Exhibit 5: Prostate Cancer Products, Market Forecast, 2001-2008
1.0 PROSTATE DISEASE OVERVIEW
1.1 Overview of Prostate Anatomy, Function and Disorders
1.2 Prostatitis
1.2.1 Types
1.2.2 Incidence and Prevalence
1.2.3 Symptoms
1.2.4 Theories of Etilogy
1.2.4.1 Bacterial Causes
1.2.4.1.1 Quinolone-Resistance of E.coli
1.2.4.1.2 Role of Chlamydial Infections
1.2.4.1.3 Role of Biofilms
1.2.4.2 Neuromuscular
1.2.4.2.1 Dysfunction of Pelvic Floor Muscles
1.2.4.2.2 Expression of Nerve Growth Factor
1.2.4.2.3 Pudendal Nerve Entrapment
1.2.4.3 Voiding Dysfunction
1.2.4.3.1 Bladder Neck Hyperplasia
1.2.4.3.2 Urine Reflux into Prostatic Ducts
1.2.4.4 Autoimmune
1.2.4.5 Other Potential Causes
1.2.5 Diagnosis
1.2.6 Treatment
1.3 Benign Prostatic Hyperplasia
1.3.1 Causes
1.3.2 Symptoms
1.3.3 Diagnosis
1.3.4 Treatment
1.3.5 Prevalence
1.4 Prostate Cancer
1.4.1 Symptoms
1.4.2 Incidence and Deaths
1.4.3 Etiology
1.4.4 Prevention
1.4.5 Diagnosis
1.4.6 Treatment
Exhibit 1-1: The Male Prostate
Exhibit 1-2: Comparison of Major Prostate Diseases
Exhibit 1-3: NIH Classification System for Prostatitis Syndromes
Exhibit 1-4: NIH Chronic Prostatitis Symptom Index
Exhibit 1-5: Selected Theories of Etiology of Chronic Prostatitis and CPPS
Exhibit 1-6: Biofilm Theory of Chronic Prostatitis
Exhibit 1-7: Potential Neuromuscular Causes of Chronic Prostatitis
Exhibit 1-8: Potential Voiding Dysfunction Causing Chronic Prostatitis
Exhibit 1-9: Prostate Cancer Incidence and Deaths, 2000-2003
Exhibit 1-10: Prostate Cancer Relative Survival Rates, 2003
Exhibit 1-11: Prostate Cancer Risk Factors
2.0 PROSTATE DISEASE DIAGNOSIS
2.1 Diagnostic Guidelines and Protocols
2.1.1 Prostate Disease Patient Outcomes Research Team
2.1.2 Prostate, Lung Colorectal and Ovarian Trial
2.1.3 American Urological Association Guidelines
2.1.4 National Institutes of Health
2.2 Protocols by Condition
2.2.1 Prostate Cancer
2.2.1.1 Screening and Diagnosis
2.2.1.2 Cancer Grading
2.2.1.3 Cancer Staging
2.2.1.4 Partin Tables
2.2.1.5 DNA Test for Prostate Cancer
2.2.2. Benign Prostatic Hyperplasia
2.2.3 Prostatitis
2.3 Prostate Disease Diagnostic Tools
2.3.1 Patient History
2.3.2 Digital Rectal Exam
2.3.3 Urinanalysis or Culture
2.3.4 PSA Tests
2.3.4.1 PSA Values and Refinements
2.3.4.2 Free PSA Test
2.3.4.3 Complexed PSA Test
2.3.4.4 RT-PCR Assays
2.3.4.5 Suppliers of PSA Test Equipment and Assays
2.3.4.5.1 Clinical Laboratory Testing
2.3.4.5.2 Point-of-Care Segment
2.3.4.6 PSA Tests Performed
2.3.4.7 PSA Test Market Analysis
2.3.5 Diagnostic Ultrasound
2.3.5.1 Technique
2.3.5.2 Equipment and Suppliers
2.3.5.3 Installations and Procedures
2.3.5.4 Diagnostic Ultrasound Market Analysis
2.3.6 Urodynamic Studies
2.3.6.1 Equipment and Suppliers
2.3.6.2 Reimbursement
2.3.6.3 Installations & Specialists Performing Procedures
2.3.6.4 Procedures
2.3.6.5 Market Analysis
2.3.7 Prostate Biopsy
2.3.7.1 Potential for Cancer Seeding
2.3.7.2 Products and Suppliers
2.3.7.3 Procedures
2.3.7.4 Market Analysis
2.3.8 Staging Studies
2.3.8.1 Imaging Studies
2.3.8.2 Pelvic Lymph Node Dissection
2.3.9 Emerging and Investigational Diagnostic Modalities
2.3.9.1 Differentiation of Prostate Cancer from BPH
2.3.9.1.1 Kallikrein Enzyme
2.3.9.1.2 Prostatic Intraepithelial Neoplasia
2.3.9.1.3 Prostate Cancer Oncogene
2.3.9.1.4 Photodynamic Laser Blood Analysis
2.3.9.2 Improved Staging and Characterization of Prostate Cancer
2.3.9.2.1 Prostascint
2.3.9.2.2 12-Lipoxygenase
2.3.9.2.3 Prostate Cancer Staging Oncogenes
2.3.9.2.4 DNA Ploidy Analysis
2.3.9.2.5 Chromosome 8p22 Deletion
2.3.9.2.6 Optical Molecular Imaging
2.3.9.2.7 SELDI Protein Profiling
2.3.9.2.8 Other Biomarker Technologies
Exhibit 2-1: Sample Questions from the AUA BPH Symptom Index
Exhibit 2-2: Screening and Diagnosis of Prostate Cancer
Exhibit 2-3: Comparison of Recommendations for Prostate Cancer Screening
Exhibit 2-4: Prostate Cancer Staging
Exhibit 2-5: Whitmore-Jewett versus TNM Prostate Cancer Staging Systems
Exhibit 2-6: Illustrations of Prostate Cancer Stages
Exhibit 2-7: Partin Tables
Exhibit 2-8: Diagnostic and Screening Tools for Prostate Disease
Exhibit 2-9: Factors Potentially Affecting PSA Levels
Exhibit 2-10: Types and Characteristics of Serum PSA
Exhibit 2-11: Probability of Cancer: Total PSA versus Free PSA Testing
Exhibit 2-12: Current and Emerging PSA Tests, 2003
Exhibit 2-13: PSA Testing, Forecast by Application, 2001-2008
Exhibit 2-14: PSA Test Products, Market Forecast by Segment, 2001-2008
Exhibit 2-15: PSA Tests, Supplier Shares, 2002
Exhibit 2-16: Selected Diagnostic Ultrasound Urology Scanners, 2003
Exhibit 2-17: TRUS, Installed Base and Procedure Forecast, 2001-2008
Exhibit 2-18: Portable TRUS Scanners, Market Forecast, 2001-2008
Exhibit 2-19: Transrectal Ultrasound Scanners, Supplier Shares, 2002
Exhibit 2-20: Overview of Major Urodynamic Studies
Exhibit 2-21: Selected Urodynamic Systems, 2003
Exhibit 2-22: Medicare Reimbursement for Urodynamic Studies, 2003
Exhibit 2-23: Urodynamic Studies, Procedure Forecast, 2001-2008
Exhibit 2-24: Urodynamic Products by Major Category, Market Forecast, 2001-2008
Exhibit 2-25: Urodynamic Systems and Consumables, Supplier Shares, 2002
Exhibit 2-26: Selected Prostate Biopsy Systems, 2003
Exhibit 2-27: Prostate Biopsies, Procedure Forecast, 2001-2008
Exhibit 2-28: Prostate Biopsy Products, Market Forecast, 2001-2008
Exhibit 2-29: Prostate Biopsy Products, Supplier Shares, 2002
Exhibit 2-30: Selected Prostate Cancer Diagnostic Technologies in Development, 2003
Exhibit 2-31: High Grade Prostatic Intraepithelial Neoplasia (PIN)
Exhibit 2-32: Selected Programs Targeting Improved Staging and Characterization of Prostate Cancer
3.0 MANAGEMENT OF PROSTATITIS
3.1 Treatment Challenges
3.2 Treatment Options
3.2.1 Drug Therapy
3.2.1.1 Antibiotic Therapy
3.2.1.1.1 Fluoroquinolones
3.2.1.1.2 Trimethoprim/Sulfamethoxazole
3.2.1.1.3 Doxycycline
3.2.1.1.4 Nitrofurantoin
3.2.1.2 Narcotic Drugs
3.2.1.3 Analgesic and Anti-Inflammatory Agents
3.2.1.4 Alpha Blockers
3.2.1.5 Intraprostatic Delivery
3.2.2 Other Medical Therapy
3.2.3 Surgical Therapy
3.2.4 Hyperthermia Therapies
3.2.4.1 Microwave Therapy
3.2.4.1.1 Transrectal Hyperthermia
3.2.4.1.2 TUMT
3.2.4.2 Radiofrequency Ablation
3.2.4.3 Interstitial Laser Coagulation
3.2.4.4 Water-Induced Thermotherapy
3.2.5 Neuromuscular Therapies
3.2.5.1 Neurotransmitter Blocker Therapy
3.2.5.2 Sacral Nerve Stimulation
3.2.6 Pelvic Floor Physical Therapy
3.3 Potential Patient Caseload
3.4 Product Opportunities
Exhibit 3-1: Prostatitis Treatment Issues and Implications
Exhibit 3-2: Current and Emerging Treatment Options for Prostatitis, 2003
Exhibit 3-3: Studies of Microwave Thermal Therapy in the Treatment of Chronic Nonbacterial Prostatitis
Exhibit 3-4: Sacral Nerves and Contiguous Structures
Exhibit 3-5: Potential Candidates for New Prostatitis Therapies, 2001-2008
4.0 BENIGN PROSTATIC HYPERPLASIA
4.1 Overview of Treatment Protocols
4.1.1 Factors Influencing Treatment Choice
4.1.2 General Trend in BPH Treatment
4.2 Watchful Waiting
4.3 Drug Therapy
4.3.1 5-Alpha-Reductase Inhibitors
4.3.1.1 Merck (Proscar)
4.3.1.2 Glaxo SmithKline (Avodart)
4.3.2 Alpha Blockers
4.3.2.1 Abbott Laboratories (Hytrin)
4.3.2.2 Boehringer-Ingelheim/Abott Laboratories (Flomax)
4.3.2.3 Pfizer (Cardura)
4.3.2.4 Sanofi-Synthelabo (Uroxatral)
4.3.2.5 Synaptic Pharmaceutical
4.3.3 Plant-Based Derivatives (Phytotherapy)
4.3.4 Clinical Comparison of Drug Options
4.3.5 Patient Forecast
4.3.6 Market Analysis
4.4 Balloon Dilatation
4.5 Surgical Interventions (Prostatectomy)
4.5.1 Transurethral Resection of the Prostate
4.5.1.1 Products
4.5.1.1.1 Traditional Devices
4.5.1.1.2 Bipolar Products
4.5.1.2 Reimbursement
4.5.1.3 Procedures
4.5.1.4 Market Analysis
4.5.2 Transurethral Incision of the Prostate
4.5.2.1 Equipment
4.5.2.2 Reimbursement and Procedures
4.5.3 Electrosurgical Vaporization of the Prostate
4.5.3.1 Benefits and Limitations
4.5.3.2 Equipment and Supplies
4.5.3.3 Procedures
4.5.3.4 Market Analysis
4.5.4 Laser-Assisted Prostatectomy
4.5.4.1 Visual Laser-Assisted Prostatectomy (VLAP)
4.5.4.2 Holmium Laser Resection of the Prostate (HoLRP)
4.5.4.2.1 Clinical Experience
4.5.4.2.2 Potential Drawbacks
4.5.4.2.3 Procedures
4.5.4.3 Photoselective Vaporization of Prostate (PVP)
4.5.4.3.1 Development History
4.5.4.3.2 Clinical Experience
4.5.4.3.3 Benefits and Limitations
4.5.4.3.4 Reimbursement
4.5.4.3.5 Settings
4.5.4.3.6 Long-Term Outcomes
4.5.4.3.7 Product Requirements/Installations
4.5.4.3.8 Procedures
4.5.4.4 Market Analysis
4.6 Minimally Invasive Treatments
4.6.1 Transurethral Microwave Thermotherapy (TUMT)
4.6.1.1 Benefits and Challenges
4.6.1.2 Clinical Experience
4.6.1.3 Products and Suppliers
4.6.1.3.1 Urologix
4.6.1.3.2 TherMatrx
4.6.1.3.3 ProstaLund/ACMI
4.6.1.3.4 Celsion Corp/Boston Scientific
4.6.1.4 Reimbursement
4.6.1.5 Procedures
4.6.1.6 Market Analysis
4.6.2 Transurethral Needle Ablation (TUNA)
4.6.2.1 Reimbursement
4.6.2.2 Procedures
4.6.2.3 Market Analysis
4.6.3 Interstitial Laser Coagulation (ILC)
4.6.3.1 Advantages and Limitations
4.6.3.2 Procedures
4.6.3.3 Market Analysis
4.6.4 Water-Induced Thermotherapy (WIT)
4.6.4.1 Clinical Experience
4.6.4.2 Products and Suppliers
4.6.4.3 Procedures and Market Analysis
4.6.5 High-Intensity Focused Ultrasound
4.6.5.1 Technique
4.6.5.2 Advantages and Limitations
4.6.5.3 Products and Suppliers
4.6.5.4 Procedures and Market Analysis
4.6.6 Chemical Ablation
4.6.6.1 Technique
4.6.6.2 Advantages and Limitations
4.6.6.3 Clinical Experience
4.6.6.4 Products and Suppliers
4.6.6.5 Procedure and Market
4.6.7 Transurethral Volume Reduction of Prostate (TUVOR)
4.6.8 Prostatic Stents
4.6.8.1 Clinical Outcomes
4.6.8.2 Products and Suppliers
4.6.8.2.1 AbbeyMoor Medical
4.6.8.2.2 Allium
4.6.8.2.3 American Medical Systems
4.6.8.2.4 Bionx Implants
4.6.8.2.5 Boston Scientific
4.6.8.2.6 ContiCare Medical
4.6.8.2.7 Endocare
4.6.8.2.8 Engineers & Doctors
4.6.8.2.9 Global Precision Medical
4.6.8.2.10 Harmonia Medical Technologies
4.6.8.2.11 InjecTx
4.6.8.2.12 Mentor Urology
4.6.8.3 Patients and Procedures
4.6.8.4 Market Analysis
Exhibit 4-1: Benigh Prostatic Hyperplasia, Patient Forecast, 2001-2008
Exhibit 4-2: Overview of Treatment Options for Benign Prostatic Hyperplasia, 2002
Exhibit 4-3: Characteristics of Major Treatments for Benign Prostatic Hyperplasia
Exhibit 4-4: Comparison of Selected BPH Drugs, 2003
Exhibit 4-5: Summary of MTOPS Study Findings
Exhibit 4-6: BPH Drug Therapy, Patient Forecast by Category, 2001-2008
Exhibit 4-7: BPH Drugs, Market Forecast by Type, 2001-2008
Exhibit 4-8: BPH Drugs, Supplier Shares, 2002
Exhibit 4-9: Transurethral Prostatectomy Techniques, 2003
Exhibit 4-10: Surgical Interventions for BPH, Procedure Forecast by Type, 2001-2008
Exhibit 4-11: TURP Cutting Loops, Market Forecast, 2001-2008
Exhibit 4-12: TURP Cutting Loops, Supplier Shares, 2002
Exhibit 4-13: Electrovaporization of Prostate Disposables, Market Forecast, 2001-2008
Exhibit 4-14: Roller Ball Devices, Supplier Shares, 2002
Exhibit 4-15: Advantages of Holmium Laser Resection of the Prostate
Exhibit 4-16: Summary of Published Results of HoLRP, 2003
Exhibit 4-17: Selected Holmium Lasers Used in Urologic Applications, 2003
Exhibit 4-18: Comparison of GreenLight PVP versus Minimally Invasive Therapies
Exhibit 4-19: BPH Laser Systems and Fibers, Market Forecast, 2001-2008
Exhibit 4-20: BPH Laser Products, Supplier Shares, 2002
Exhibit 4-21 Current and Emerging Minimally Invasive Treatment Options for BPH
Exhibit 4-22: Minimally Invasive BPH Treatments, Procedure Forecast, 2001-2008
Exhibit 4-23: Selected Transurethral Microwave Thermotherapy Systems, 2003
Exhibit 4-24: Benefits of Targis System Express Protocol
Exhibit 4-25: Transurethral Microwave Thermal Therapy, Market Forecast, 2001-2008
Exhibit 4-26: Transurethral Microwave Thermal Therapy, Supplier Shares, 2002
Exhibit 4-27: Summary of Worldwide Results for TUNA Procedure
Exhibit 4-28: Transurethral Needle Ablation, Market Forecast, 2001-2008
Exhibit 4-29: Interstitial Laser Coagulation, Market Forecast, 2001-2008
Exhibit 4-30: Water-Induced Thermal Therapy, Market Forecast, 2001-2008
Exhibit 4-31: High Intensity Focused Ultrasound, Market Forecast, 2001-2008
Exhibit 4-32: Advantages and Limitations of Ethanol Alcohol Ablation of Prostate
Exhibit 4-33: Ethanol Ablation of the Prostate, Market Forecast, 2001-2008
Exhibit 4-34: Efficacy of Prostatic Stents
Exhibit 4-35: Current and Emerging Prostatic Urethral Stents, 2003
Exhibit 4-36: Selected Current and Emerging Prostatic Urethral Stents, 2003
Exhibit 4-37: Potential Obstacles to Broad Adoption of Prostatic Urethral Stents
Exhibit 4-38: Prostatic Urethral Stents, Procedure & Market Forecast, 2001-2008
5.0 PROSTATE CANCER
5.1 Therapeutic Options
5.2 Watchful Waiting
5.3 Radical Prostatectomy
5.3.1 Techniques
5.3.1.1 Open Radical Prostatectomy
5.3.1.2 Laparoscopic Radical Prostatectomy
5.3.1.2.1 Experience Base
5.3.1.2.2 Learning Curve & Conversion Rate
5.3.1.2.3 Complications & Techniques
5.3.1.2.4 Recent Clinical Outcomes
5.3.1.2.5 Equipment and Products
5.3.1.2.6 Procedure Costs
5.3.1.2.7 Selected Observations on Procedure
5.3.2 Procedures
5.4 External Beam Radiation Therapy
5.4.1 Equipment
5.4.2 Techniques
5.4.2.1 Conventional External Beam Radiation Therapy
5.4.2.2 Three-Dimensional Conformal EBRT
5.4.2.3 Intensity Modulated Radiation Therapy
5.4.2.4 Other Modalities
5.4.2.4.1 Fractionated Stereotactic Body Radiosurgery
5.4.2.4.2 Proton Beam Therapy
5.4.3 Reimbursement
5.4.4 Procedures
5.5 Brachytherapy
5.5.1 Clinical and Product Developments
5.5.2 Techniques
5.5.2.1 Permanent Implantation Brachytherapy
5.5.2.2 Temporary Implantation Brachytherapy
5.5.2.2.1 Treatment Protocol
5.5.2.2.2 Advantages and Limitations
5.5.2.2.3 Equipment
5.5.3 Radiation Sources
5.5.3.1 Iodine-125
5.5.3.2 Palladium-103
5.5.3.3 Iridium-192
5.5.3.4 Bioabsorbable Radioactive Implants
5.5.4 Reimbursement
5.5.5 Procedures
5.5.6 Market Analysis
5.6 Cryosurgical Ablation
5.6.1 Technique
5.6.2 Complications
5.6.3 Advantages and Limitations
5.6.4 Indications and Outcomes
5.6.5 Procedure Cost and Reimbursement
5.6.6 Products
5.6.6.1 Endocare
5.6.6.2 Galil Medical/Oncura
5.6.7 Procedures
5.6.8 Market Analysis
5.7 High Intensity Focused Ultrasound (HIFU)
5.7.1 Focus Surgery
5.7.2 EDAP Technomed
5.7.3 Clinical Experience
5.7.4 Procedures
5.7.5 Market Analysis
5.8 Photodynamic Therapy
5.8.1 Technique
5.8.2 Advantages and Limitations
5.8.3 Clinical Experience in Prostate Cancer
5.8.4 Products and Programs
5.8.5 Procedures
5.9 Chemotherapy
5.10 Prophylaxis
5.10.1 5-Alpha Reductase Inhibitors
5.10.2 Other Programs
5.11 Hormone Therapy
5.11.1 LHRH-A's
5.11.2 Antiandrogens
5.11.3 Other Products
5.11.4 Developments
5.11.4.1 Praecis Pharmaceuticals
5.11.4.2 Epic Therapeutics
5.11.4.3 Valera Pharmaceuticals
5.11.4.4 Oakwood Laboratories
5.11.5 Market Forecast
5.12 Emerging Biologic and Other Approaches
5.12.1 Abbott Laboratories
5.12.2 Aronex Pharmaceuticals
5.12.3 Cell Genesys, Inc.
5.12.4 Cell Pathways/OSI Pharmaceuticals
5.12.5 Dendreon Corporation
5.12.6 Genentech
5.12.7 Genta Incorporated
5.12.8 Genistein
5.12.9 GlycoGenesys
5.12.10 Introgen Therapeutics
5.12.11 Medarex
5.12.12 MGI Pharma
5.12.13 Millenium Pharmaceuticals
5.12.14 Northwest Biopharmaceuticals
5.12.15 OncoGenex Technologies
5.12.16 Pharmacia & Upjohn (Sugen)
5.12.17 Sidney Kimmel Comprehensive Cancer Center
5.12.18 Therion Biologics Corporation
Exhibit 5-1: Overview of Treatment Options for Prostate Cancer, 2003
Exhibit 5-2: Comparison of Established Prostate Cancer Treatment Options
Exhibit 5-3: Early Clinical Outcomes of Laparoscopic Radical Prostatectomy
Exhibit 5-4: Complications Associated with Laparoscopic Radical Prostatectomy
Exhibit 5-5: Cost of Devices Used to Perform Laparoscopic Radical Prostatectomy
Exhibit 5-6: Costs of Open vs Laparoscopic Radical Prostatectomy in France
Exhibit 5-7: Radical Prostatectomy, Procedure Forecast by Type, 2001-2008
Exhibit 5-8: Comparison of External Beam Radiation Therapy Modalities, 2003
Exhibit 5-9: External Beam Radiation Therapy, Patient Forecasts, 2001-2008
Exhibit 5-10: Comparison of Permanent and Temporary Implantation Brachytherapy
Exhibit 5-11: Major Radioisotopes Used for Prostate Brachytherapy
Exhibit 5-12: Suppliers of Prostate Brachytherapy Seeds, 2003
Exhibit 5-13: Overview of Prostate Brachytherapy Reimbursement
Exhibit 5-14: Prostate Brachytherapy, Patient Forecasts by Type, 2001-2008
Exhibit 5-15: Prostate Brachytherapy Products, Market Forecast, 2001-2008
Exhibit 5-16: Permanent Prostate Brachytherapy, Market Forecast, 2001-2008
Exhibit 5-17: Temp Prostate Brachytherapy Products, Market Forecast, 2001-2008
Exhibit 5-18: Prostate Brachytherapy Seeds, Supplier Shares, 2002
Exhibit 5-19: Overview of Cryosurgical Ablation of the Prostate
Exhibit 5-20: Cryosurgical Systems Targeting Prostate Cancer
Exhibit 5-21: Cryosurgical Ablation of Prostate, Procedure Forecast, 2001-2008
Exhibit 5-22: Prostate Cryotherapy Disposables, Market Forecast, 2001-2008
Exhibit 5-23: Prostate Cryotherapy Disposables, Supplier Shares, 2002
Exhibit 5-24: Prostate High Intensity Focused Ultrasound Systems, 2003
Exhibit 5-25: Prostate Cancer HIFU, Procedure Forecast, 2004-2008
Exhibit 5-26 Prostate Cancer HIFU, Market Forecast, 2001-2008
Exhibit 5-27 : Clinical Trials of PDT for the Treatment of Prostate Cancer
Exhibit 5-28: Overview of Photosensitizer R&D Targeting Prostate Cancer
Exhibit 5-29: Prostate Cancer Hormone Therapy, Market Forecast, 2001-2008
Exhibit 5-30: Prostate Hormonal Therapy, Supplier Shares, 2002
Exhibit 5-31: Approaches to Cancer Gene Therapy
Exhibit 5-32: Emerging Prostate Cancer Biological Treatment Options
6.0 COMPANY PROFILES
6.1 Abbott Laboratories
6.2 ACMI Corporation
6.3 American Medical Systems
6.4 AstraZeneca plc
6.5 C.R. Bard
6.6 Beckman Coulter (Hybritech)
6.7 B-K Medical Corporation
6.8 EDAP Technomed
6.9 Endocare
6.10 Focus Surgery
6.11 Gyrus Medical
6.12 Laborie Medical Technologies
6.13 Laserscope
6.14 Life-Tech
6.15 Medtronic
6.16 Mentor Corporation
6.17 Oakwood Laboratories
6.18 Oncura (Amersham Health, Galil Medical)
6.19 Praecis Pharmaceuticals
6.20 ProstaLund
6.21 TAP Pharmaceuticals
6.22 Theragenics
6.23 Urologix
6.24 Varian Medical Systems
APPENDIX: COMPANY LIST